Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study.

Yan LeWenlin YangJianyun LuJiang XianQing GuoChunyun HuangQing SunHuiping WangMingye BiHaiying WangSongmei GengBin YangAi-E XuYong Cui Xiao-Yong ManYi ZhaoLitao ZhangLinfeng LiZhiqiang SongJin ChenHao ChengWei ZhuXiuping HanShanshan LiTong LinChunlei ZhangJiuhong LiYanling LiYangfeng DingLinda WangYuefang ZhuLeihong Flora Xiang

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

FMX101 4% treatment for 12 weeks could lead to significantly reduced ILC and nILC, and improved IGA treatment success rate in Chinese subjects with moderate-to-severe facial AV. It also showed a well acceptable safe and tolerability profile.

Keyphrases

double blind
placebo controlled
clinical trial
open label
early onset
phase iii
soft tissue
preterm birth